Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Medullary Thyroid Cancer Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Medullary Thyroid Cancer Overview | 9 | 1 |
| Pipeline Products for Medullary Thyroid Cancer Comparative Analysis | 10 | 1 |
| Medullary Thyroid Cancer Therapeutics under Development by Companies | 11 | 1 |
| Medullary Thyroid Cancer Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Medullary Thyroid Cancer Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Medullary Thyroid Cancer Products under Development by Companies | 16 | 1 |
| Medullary Thyroid Cancer Products under Investigation by Universities/Institutes | 17 | 1 |
| Medullary Thyroid Cancer Companies Involved in Therapeutics Development | 18 | 10 |
| AbbVie Inc | 18 | 1 |
| Advenchen Laboratories, LLC | 19 | 1 |
| Bayer AG | 20 | 1 |
| Boehringer Ingelheim GmbH | 21 | 1 |
| Celgene Corporation | 22 | 1 |
| Hutchison MediPharma Limited | 23 | 1 |
| Immunomedics, Inc. | 24 | 1 |
| Nerviano Medical Sciences S.r.l. | 25 | 1 |
| Novartis AG | 26 | 1 |
| Pfizer Inc. | 27 | 1 |
| Medullary Thyroid Cancer Therapeutics Assessment | 28 | 11 |
| Assessment by Monotherapy Products | 28 | 1 |
| Assessment by Target | 29 | 3 |
| Assessment by Mechanism of Action | 32 | 3 |
| Assessment by Route of Administration | 35 | 2 |
| Assessment by Molecule Type | 37 | 2 |
| Drug Profiles | 39 | 57 |
| AL-3818 Drug Profile | 39 | 3 |
| CLM-29 Drug Profile | 42 | 1 |
| CLM-3 Drug Profile | 43 | 1 |
| CLM-94 Drug Profile | 44 | 1 |
| everolimus Drug Profile | 45 | 12 |
| GI-6207 Drug Profile | 57 | 2 |
| HMPL-012 Drug Profile | 59 | 3 |
| nintedanib Drug Profile | 62 | 10 |
| NMS-616 Drug Profile | 72 | 1 |
| pasireotide Drug Profile | 73 | 4 |
| regorafenib Drug Profile | 77 | 10 |
| rovalpituzumab tesirine Drug Profile | 87 | 2 |
| Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer Drug Profile | 89 | 1 |
| Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer Drug Profile | 90 | 1 |
| SYN-001 Drug Profile | 91 | 1 |
| temsirolimus Drug Profile | 92 | 2 |
| TF-2 Drug Profile | 94 | 2 |
| Medullary Thyroid Cancer Dormant Projects | 96 | 1 |
| Medullary Thyroid Cancer Discontinued Products | 97 | 1 |
| Medullary Thyroid Cancer Product Development Milestones | 98 | 1 |
| Featured News &Press Releases | 98 | 1 |
| Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer | 98 | 1 |
| Appendix | 99 | 2 |
| Methodology | 99 | 1 |
| Coverage | 99 | 1 |
| Secondary Research | 99 | 1 |
| Primary Research | 99 | 1 |
| Expert Panel Validation | 99 | 1 |
| Contact Us | 99 | 1 |
| Disclaimer | 100 | 1 |